Novo Nordisk stock struggles as AI initiative GPT-Rosalind launches against a backdrop of revenue decline, patent expiry, and a major share buyback program.<\/p>\n
Novo Nordisk shares, trading at \u20ac34.44, are caught in a strategic tug-of-war. The Danish pharmaceutical giant is simultaneously launching a major AI initiative while navigating one of its most severe revenue downturns in recent memory, with the stock down nearly 23% year-to-date and more than 50% below its June 2025 peak of \u20ac70.13.<\/p>\n
This pressure follows a year of profound internal upheaval. In 2025, CEO Mike Doustdar\u2019s sweeping cost-cutting program eliminated approximately 9,000 jobs, roughly 10% of the global workforce. In a stark reversal, the company has already hired 2,000 new employees this year, focusing recruitment squarely on core areas like production and research. This strategic realignment comes at a critical juncture for the beleaguered equity.<\/p>\n
Financially, the headwinds are substantial. For the full 2026 fiscal year, management anticipates a revenue decline of between 5% and 13%. This forecast is pressured by intense competition in the lucrative weight-loss drug market, significant price discounts in the US, and looming patent expirations. In a key development, a crucial patent for the active ingredient semaglutid expired in China in March, opening the door for local generic manufacturers after a three-year legal defense by Novo Nordisk.<\/p>\n
Amidst this challenging backdrop, the company is deploying capital to support its share price. A share buyback program worth 15 billion Danish kroner is underway, with the current tranche running until early May 2026. Technical indicators reflect the stock’s strain, with a Relative Strength Index (RSI) reading of 25 signaling deeply oversold conditions.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n On the innovation front, Novo Nordisk is betting heavily on artificial intelligence to reshape its future. On April 17-18, 2026, the company unveiled “GPT-Rosalind,” a specialized AI model for biology and translational medicine developed in collaboration with OpenAI. The ambition is to drastically shorten the traditional 10-to-15-year drug development timeline. Internally, the model has reportedly outperformed 95% of human experts in predicting RNA sequences. Pilot programs are active across the value chain, with full integration targeted by the end of 2026.<\/p>\n The product pipeline offers some counterbalance to the financial concerns. The company recently launched a higher-dose Wegovy injection, with clinical data showing an average weight loss of around 21%. Furthermore, an oral formulation of Wegovy demonstrated a 14% average weight reduction over 64 weeks in a study, compared to 2.4% for placebo. Notably, about 28% of participants on the 25mg maintenance dose lost more than one-fifth of their body weight.<\/p>\n Independent research is also shedding new light on patient experiences. An April 2026 study published in Nature, using AI to analyze over 400,000 social media reports on GLP-1 drugs, confirmed gastrointestinal issues as the most common side effect at 37%. It also uncovered less-documented symptoms, including menstrual cycle changes for nearly 4% of female users.<\/p>\n